JP2018512162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512162A5 JP2018512162A5 JP2017554057A JP2017554057A JP2018512162A5 JP 2018512162 A5 JP2018512162 A5 JP 2018512162A5 JP 2017554057 A JP2017554057 A JP 2017554057A JP 2017554057 A JP2017554057 A JP 2017554057A JP 2018512162 A5 JP2018512162 A5 JP 2018512162A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- dna
- cell
- sequence
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 94
- 210000004027 cell Anatomy 0.000 claims description 91
- 108020004414 DNA Proteins 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 34
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 28
- 230000004048 modification Effects 0.000 claims description 26
- 238000012986 modification Methods 0.000 claims description 26
- 238000001890 transfection Methods 0.000 claims description 21
- 230000003213 activating effect Effects 0.000 claims description 15
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 10
- 238000004520 electroporation Methods 0.000 claims description 8
- 101710163270 Nuclease Proteins 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 230000004075 alteration Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 108700019146 Transgenes Proteins 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 210000004986 primary T-cell Anatomy 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 108091033409 CRISPR Proteins 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 108020005004 Guide RNA Proteins 0.000 claims description 2
- 108010061833 Integrases Proteins 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 238000010459 TALEN Methods 0.000 claims description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 2
- 102000008579 Transposases Human genes 0.000 claims description 2
- 108010020764 Transposases Proteins 0.000 claims description 2
- 238000002617 apheresis Methods 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 230000010354 integration Effects 0.000 claims description 2
- 238000011031 large-scale manufacturing process Methods 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003833 cell viability Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 102000012330 Integrases Human genes 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562146618P | 2015-04-13 | 2015-04-13 | |
| US62/146,618 | 2015-04-13 | ||
| PCT/US2016/027253 WO2016168275A1 (en) | 2015-04-13 | 2016-04-13 | Methods and compositions for modifying genomic dna |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512162A JP2018512162A (ja) | 2018-05-17 |
| JP2018512162A5 true JP2018512162A5 (enExample) | 2019-05-23 |
| JP6885876B2 JP6885876B2 (ja) | 2021-06-16 |
Family
ID=55806847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554057A Active JP6885876B2 (ja) | 2015-04-13 | 2016-04-13 | ゲノムｄｎａを改変するための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11608511B2 (enExample) |
| EP (1) | EP3283635B1 (enExample) |
| JP (1) | JP6885876B2 (enExample) |
| KR (2) | KR20250058073A (enExample) |
| CN (1) | CN107980059B (enExample) |
| CA (1) | CA2982759C (enExample) |
| ES (1) | ES2926467T3 (enExample) |
| WO (1) | WO2016168275A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| AU2016326711B2 (en) | 2015-09-24 | 2022-11-03 | Editas Medicine, Inc. | Use of exonucleases to improve CRISPR/Cas-mediated genome editing |
| EP3433363A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| WO2017180694A1 (en) | 2016-04-13 | 2017-10-19 | Editas Medicine, Inc. | Cas9 fusion molecules gene editing systems, and methods of use thereof |
| US11293021B1 (en) | 2016-06-23 | 2022-04-05 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| EP3555273B1 (en) | 2016-12-16 | 2024-05-22 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| PL3645719T3 (pl) | 2017-06-30 | 2022-06-20 | Inscripta, Inc. | Sposoby, moduły, przyrządy i systemy zautomatyzowanego przetwarzania komórek |
| WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
| US10738327B2 (en) | 2017-08-28 | 2020-08-11 | Inscripta, Inc. | Electroporation cuvettes for automation |
| CN114958772A (zh) | 2017-09-01 | 2022-08-30 | 隆萨沃克斯维尔股份有限公司 | 端到端细胞治疗自动化 |
| CN111372650A (zh) | 2017-09-30 | 2020-07-03 | 因思科瑞普特公司 | 流通式电穿孔仪器 |
| WO2019190874A1 (en) | 2018-03-29 | 2019-10-03 | Inscripta, Inc. | Automated control of cell growth rates for induction and transformation |
| US10376889B1 (en) | 2018-04-13 | 2019-08-13 | Inscripta, Inc. | Automated cell processing instruments comprising reagent cartridges |
| US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
| US10501738B2 (en) | 2018-04-24 | 2019-12-10 | Inscripta, Inc. | Automated instrumentation for production of peptide libraries |
| US10526598B2 (en) | 2018-04-24 | 2020-01-07 | Inscripta, Inc. | Methods for identifying T-cell receptor antigens |
| AU2019288669B2 (en) | 2018-06-21 | 2025-06-26 | R&D Systems, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| US10533152B1 (en) | 2018-08-14 | 2020-01-14 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| US10532324B1 (en) | 2018-08-14 | 2020-01-14 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| US11965154B2 (en) | 2018-08-30 | 2024-04-23 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| SG11202102841WA (en) | 2018-09-28 | 2021-04-29 | Octane Biotech Inc | Magnetic separation |
| EP3870697A4 (en) | 2018-10-22 | 2022-11-09 | Inscripta, Inc. | GMO ENZYMES |
| US11214781B2 (en) | 2018-10-22 | 2022-01-04 | Inscripta, Inc. | Engineered enzyme |
| US11718833B2 (en) | 2018-12-21 | 2023-08-08 | Lonza Walkersville, Inc. | Automated production of viral vectors |
| US11714096B2 (en) | 2018-12-21 | 2023-08-01 | Octane Biotech Inc. | Carousel for modular biologic production units |
| CN113498432A (zh) | 2019-02-08 | 2021-10-12 | 隆萨沃克斯维尔股份有限公司 | 用于自动化生物反应器的细胞浓缩方法和装置 |
| CA3134168A1 (en) | 2019-03-25 | 2020-10-01 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| EP3953477A4 (en) | 2019-06-06 | 2022-06-22 | Inscripta, Inc. | HARDENING FOR RECURSIVE NUCLEIC ACID-DRIVEN CELL EDITING |
| CA3139124C (en) | 2019-06-21 | 2023-01-31 | Inscripta, Inc. | Genome-wide rationally-designed mutations leading to enhanced lysine production in e. coli |
| US10927385B2 (en) | 2019-06-25 | 2021-02-23 | Inscripta, Inc. | Increased nucleic-acid guided cell editing in yeast |
| JP7696340B2 (ja) | 2019-10-24 | 2025-06-20 | オクタン バイオテック インコーポレーテッド | 改善された細胞接触面を有する細胞培養チャンバ |
| KR20220097457A (ko) | 2019-11-11 | 2022-07-07 | 론자 워커스빌 아이엔씨. | 자동화된 세포 처리를 위한 품질 관리 방법 |
| US11203762B2 (en) | 2019-11-19 | 2021-12-21 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
| KR102776469B1 (ko) | 2019-12-10 | 2025-03-05 | 인스크립타 인코포레이티드 | 신규 mad 뉴클레아제 |
| US10704033B1 (en) | 2019-12-13 | 2020-07-07 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| CA3157127A1 (en) | 2019-12-18 | 2021-06-24 | Aamir MIR | Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells |
| US10689669B1 (en) | 2020-01-11 | 2020-06-23 | Inscripta, Inc. | Automated multi-module cell processing methods, instruments, and systems |
| EP4096770A1 (en) | 2020-01-27 | 2022-12-07 | Inscripta, Inc. | Electroporation modules and instrumentation |
| US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
| US11787841B2 (en) | 2020-05-19 | 2023-10-17 | Inscripta, Inc. | Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli |
| US11299731B1 (en) | 2020-09-15 | 2022-04-12 | Inscripta, Inc. | CRISPR editing to embed nucleic acid landing pads into genomes of live cells |
| CN112195193A (zh) * | 2020-09-30 | 2021-01-08 | 上海交通大学 | 单链dna在基因转染中的应用 |
| US11512297B2 (en) | 2020-11-09 | 2022-11-29 | Inscripta, Inc. | Affinity tag for recombination protein recruitment |
| US11306298B1 (en) | 2021-01-04 | 2022-04-19 | Inscripta, Inc. | Mad nucleases |
| US11332742B1 (en) | 2021-01-07 | 2022-05-17 | Inscripta, Inc. | Mad nucleases |
| US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| ATE160821T1 (de) | 1990-06-11 | 1997-12-15 | Nexstar Pharmaceuticals Inc | Nukleinsäureliganden |
| ATE272311T1 (de) | 1993-03-23 | 2004-08-15 | Cbr Lab Inc | Verfahren und vorrichtung zur einkapselung biologisch aktiver substanzen in zellen |
| JPH0844143A (ja) | 1993-06-29 | 1996-02-16 | Toshiba Corp | 帯電装置並びに該帯電装置を備えた画像形成装置 |
| US6074605A (en) | 1995-03-10 | 2000-06-13 | Entremed, Inc. | Flow electroporation chamber and method |
| CN1195997A (zh) | 1995-03-10 | 1998-10-14 | 恩特雷麦德有限公司 | 流式电穿孔室和方法 |
| US6773669B1 (en) | 1995-03-10 | 2004-08-10 | Maxcyte, Inc. | Flow electroporation chamber and method |
| US5720921A (en) | 1995-03-10 | 1998-02-24 | Entremed, Inc. | Flow electroporation chamber and method |
| US7067318B2 (en) * | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| JP4031033B2 (ja) * | 1995-05-04 | 2008-01-09 | アメリカ合衆国 | Ｔ細胞の改良トランスフェクション法 |
| US6090617A (en) | 1996-12-05 | 2000-07-18 | Entremed, Inc. | Flow electroporation chamber with electrodes having a crystalline metal nitride coating |
| DE69841452D1 (de) | 1997-02-28 | 2010-03-04 | Kyowa Hakko Kirin Co Ltd | Humanes Chromosomfragment und ein Vektor, der dies enthält |
| AU2001289104A1 (en) | 2000-09-15 | 2002-03-26 | Deltagen, Inc. | Methods of producing cells and animals comprising targeted gene modifications |
| WO2002026966A2 (en) | 2000-09-29 | 2002-04-04 | Ecole Polytechnique Federale De Lausanne | Transfection using plasmid preparations |
| US7029916B2 (en) | 2001-02-21 | 2006-04-18 | Maxcyte, Inc. | Apparatus and method for flow electroporation of biological samples |
| AU2002326717A1 (en) | 2001-08-22 | 2003-03-10 | Maxcyte, Inc. | Apparatus and method for electroporation of biological samples |
| EP1565555A4 (en) | 2002-09-30 | 2008-07-09 | Maxcyte Inc | DEVICE AND METHOD FOR STRETCH ELECTROPORATION |
| WO2004074451A2 (en) | 2003-02-18 | 2004-09-02 | Maxcyte, Inc. | Loading of cells with antigens by electroporation |
| US8409861B2 (en) * | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| AU2005245871A1 (en) | 2004-05-12 | 2005-12-01 | Maxcyte, Inc. | Methods and devices related to a regulated flow electroporation chamber |
| US7531327B2 (en) | 2004-07-23 | 2009-05-12 | Immunomedics, Inc. | Methods and compositions for increasing longevity and protein yield from a cell culture |
| SG163592A1 (en) | 2004-07-23 | 2010-08-30 | Immunomedics Inc | Methods and compositions for increasing longevity and protein yield from a cell culture |
| US20070059833A1 (en) | 2005-09-07 | 2007-03-15 | Maxcyte, Inc. | Use of Nucleases to Improve Viability and Enhance Transgene Expression in Transfected Cells |
| CA2648778A1 (en) | 2006-04-10 | 2007-10-18 | The Regents Of The University Of California | Method for culturing cells on removable pallets for subsequent cell expansion and analysis |
| CA2687688C (en) | 2007-05-23 | 2017-03-28 | Sangamo Biosciences, Inc. | Methods and compositions for increased transgene expression in t cells |
| US9534246B2 (en) | 2010-07-01 | 2017-01-03 | Glaxo Group Limited | Method for selecting high producing cell lines |
| KR20180121665A (ko) | 2010-07-23 | 2018-11-07 | 시그마-알드리치 컴퍼니., 엘엘씨 | 표적화 엔도뉴클레아제 및 단일-가닥 핵산을 사용하는 게놈 편집 |
| JP6188703B2 (ja) | 2011-10-27 | 2017-08-30 | サンガモ セラピューティクス， インコーポレイテッド | Ｈｐｒｔ遺伝子座を修飾するための方法および組成物 |
| WO2013139994A1 (en) | 2012-03-23 | 2013-09-26 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | A novel method of producing an oocyte carrying a modified target sequence in its genome |
| CA2871524C (en) * | 2012-05-07 | 2021-07-27 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration of transgenes |
| RU2014153918A (ru) | 2012-06-12 | 2016-07-27 | Дженентек, Инк. | Способы и композиции для получения условно нокаутных аллелей |
| CN102839214A (zh) | 2012-09-06 | 2012-12-26 | 许汉鹏 | 筛选真核细胞基因组内特定基因调控相关机制和分子的方法 |
| WO2014059173A2 (en) * | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| JP6683598B2 (ja) | 2013-03-15 | 2020-04-22 | マックスサイト インコーポレーティッド | 安定なトランスフェクトされた細胞を生成するための方法および組成物 |
| CN103224947B (zh) * | 2013-04-28 | 2015-06-10 | 陕西师范大学 | 一种基因打靶系统 |
| WO2014191128A1 (en) * | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| ES2883131T3 (es) * | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| WO2014204725A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| ES2962509T3 (es) | 2014-04-14 | 2024-03-19 | Maxcyte Inc | Métodos y composiciones para modificar ADN genómico |
| WO2016036754A1 (en) | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification |
-
2016
- 2016-04-13 CN CN201680031891.4A patent/CN107980059B/zh active Active
- 2016-04-13 WO PCT/US2016/027253 patent/WO2016168275A1/en not_active Ceased
- 2016-04-13 JP JP2017554057A patent/JP6885876B2/ja active Active
- 2016-04-13 US US15/566,320 patent/US11608511B2/en active Active
- 2016-04-13 CA CA2982759A patent/CA2982759C/en active Active
- 2016-04-13 KR KR1020257013453A patent/KR20250058073A/ko active Pending
- 2016-04-13 KR KR1020177032721A patent/KR20170135966A/ko not_active Ceased
- 2016-04-13 ES ES16718143T patent/ES2926467T3/es active Active
- 2016-04-13 EP EP16718143.7A patent/EP3283635B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512162A5 (enExample) | ||
| JP2017513477A5 (enExample) | ||
| JP7471289B2 (ja) | 抗ｌｉｖ１免疫細胞癌療法 | |
| US20250333468A1 (en) | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene | |
| KR20230074515A (ko) | 개선된 기능성 및 지속성을 갖는 붕괴된 레그나제-1 및/또는 tgfbrii를 지니는 유전자 조작된 t 세포 | |
| US12344656B2 (en) | Genetically engineered T cells having improved persistence in culture | |
| EP4251741A1 (en) | Gene-edited natural killer cells | |
| JP2023524976A (ja) | 必須遺伝子ノックインによる選択 | |
| WO2016071513A1 (en) | Improved method for the generation of genetically modified cells | |
| US20230083383A1 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| Basar et al. | Large-scale GMP-compliant CRISPR-Cas9–mediated deletion of the glucocorticoid receptor in multivirus-specific T cells | |
| JP2022550599A (ja) | 操作されたデュアルガイド核酸を有するｃｒｉｓｐｒシステム | |
| EP4419672A2 (en) | Compositions and methods for targeting, editing, or modifying genes | |
| US20250034558A1 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| WO2023225035A2 (en) | Compositions and methods for engineering cells | |
| EP4342983A1 (en) | Method for modifying cell | |
| WO2023233342A2 (en) | Gene-edited natural killer cells | |
| EP4504221A2 (en) | Compositions and methods for generating cells with reduced immunogenicty | |
| WO2024233505A1 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| EP4561639A2 (en) | Compositions and methods for genome editing | |
| WO2024037461A1 (zh) | 工程化免疫细胞及其制备方法 | |
| JP2025522812A (ja) | Ｇｐｃ－３を標的とするキメラ抗原受容体、及び治療的使用目的でそのようなキメラ抗原受容体を発現する免疫細胞 | |
| HK40013246B (zh) | 用具有工程化穏定的内源性foxp3基因表达的cd4 t细胞治疗自身免疫疾病的方法 |